Baillie Gifford & Co Portfolio holdings
Baillie Gifford & Co., founded in 1908 by Lt Col Augustus Baillie and Carlyle Gifford and headquartered in Edinburgh, Scotland, is an independent, partnership-owned investment management firm renowned for its long-term, growth-oriented approach, managing over £230 billion ($290 billion USD) in assets as of late 2024. Focusing primarily on global equities, the firm serves institutional clients like pension funds and retail investors through mutual funds and investment trusts, such as the Scottish Mortgage Investment Trust, emphasizing fundamental research into innovative, high-growth companies—often holding stakes in firms like Tesla and Amazon for decades. With around 2,000 employees across offices in London, New York, Hong Kong, and beyond, Baillie Gifford operates without external ownership pressures, allowing its 58 partners to prioritize patience and conviction over short-term market trends. Known for its low-profile culture and ESG integration, the firm has earned a reputation as a thoughtful, contrarian investor in a world of rapid-fire trading.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Moderna
MRNA
|
+$3.05B |
| 2 |
Coupang
CPNG
|
+$1.02B |
| 3 |
Trade Desk
TTD
|
+$941M |
| 4 |
Affirm
AFRM
|
+$795M |
| 5 |
Bilibili
BILI
|
+$729M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Tesla
TSLA
|
+$8.35B |
| 2 |
Alphabet (Google) Class C
GOOG
|
+$1.34B |
| 3 |
NIO
NIO
|
+$810M |
| 4 |
Meta Platforms (Facebook)
META
|
+$804M |
| 5 |
Amazon
AMZN
|
+$792M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Consumer Discretionary | 31.68% |
| 2 | Healthcare | 19.13% |
| 3 | Technology | 16.8% |
| 4 | Communication Services | 14.58% |
| 5 | Financials | 5.88% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
EB
151
DELISTED
Eventbrite
EB
| $86.6M | 0.05% |
3,908,734
+399,332
| +11% | +$8.04M |
|
152
MakeMyTrip
MMYT
$5.64B
| $83.4M | 0.05% |
2,642,107
+9,194
| +0.3% | +$292K |
|
153
IPG Photonics
IPGP
$3.84B
| $79.5M | 0.04% |
377,017
+29,152
| +8% | +$6.62M |
|
154
Procter & Gamble
PG
$339B
| $78.3M | 0.04% |
578,298
+30,450
| +6% | +$3.97M |
|
|
SWAV
155
DELISTED
Shockwave Medical, Inc. Common Stock
SWAV
| $75.6M | 0.04% |
580,278
+79,835
| +16% | +$9.58M |
|
|
AGR
156
DELISTED
Avangrid, Inc.
AGR
| $74M | 0.04% |
1,486,287
+1,983
| +0.1% | +$93K |
|
157
Q2 Holdings
QTWO
$3.92B
| $71.9M | 0.04% |
717,321
+61,403
| +9% | +$7.63M |
|
158
LiveRamp
RAMP
$2.3B
| $71.9M | 0.04% |
1,385,419
+179,432
| +15% | +$12.2M |
|
159
LivePerson
LPSN
$32.3M
| $68M | 0.04% |
85,989
+3,081
| +4% | +$2.85M |
|
160
DTE Energy
DTE
$29.1B
| $63.8M | 0.04% |
562,655
+736
| +0.1% | +$77.3K |
|
161
Prologis
PLD
$133B
| $63.5M | 0.04% |
+599,500
| New | +$61.1M |
|
162
PepsiCo
PEP
$190B
| $61.8M | 0.03% |
436,664
+22,379
| +5% | +$3.07M |
|
163
Rexford Industrial Realty
REXR
$8.19B
| $61.7M | 0.03% |
+1,224,400
| New | +$60.2M |
|
|
ADAP
164
DELISTED
Adaptimmune Therapeutics
ADAP
| $60.9M | 0.03% |
11,467,517
+1,109,737
| +11% | +$6.35M |
|
165
NextEra Energy
NEE
$177B
| $59.1M | 0.03% |
781,807
+769,751
| +6,385% | +$60.1M |
|
|
YSG
166
Yatsen Holding
YSG
$319M
| $58.5M | 0.03% |
947,423
+5,082
| +0.5% | +$462K |
|
167
iShares Silver Trust
SLV
$30.7B
| $58.2M | 0.03% |
2,493,600
-13,300
| -0.5% | -$324K |
|
168
Ambarella
AMBA
$3.81B
| $57.9M | 0.03% |
576,252
-1,141
| -0.2% | -$124K |
|
|
BZUN
169
Baozun
BZUN
$172M
| $57.8M | 0.03% |
1,515,755
+1,647
| +0.1% | +$70.3K |
|
|
DRE
170
DELISTED
Duke Realty Corp.
DRE
| $57.4M | 0.03% |
+1,369,380
| New | +$55.2M |
|
171
C.H. Robinson
CHRW
$17.5B
| $57.3M | 0.03% |
600,712
+30,107
| +5% | +$2.81M |
|
172
Consolidated Edison
ED
$39.9B
| $57.3M | 0.03% |
765,528
+2,712
| +0.4% | +$191K |
|
|
ZUO
173
DELISTED
Zuora, Inc.
ZUO
| $56.9M | 0.03% |
3,844,957
+822,537
| +27% | +$12.3M |
|
|
GRFS
174
Grifois
GRFS
$5.4B
| $56.2M | 0.03% |
3,252,148
-130,784
| -4% | -$2.26M |
|
|
CELL
175
DELISTED
PhenomeX Inc. Common Stock
CELL
| $56.2M | 0.03% |
1,119,343
+342,283
| +44% | +$23.3M |
|
Similar funds
Baillie Gifford & Co's Q1 2021 Portfolio in Review
As of Q1 2021, Baillie Gifford & Co held 469 positions worth $179B, down 0.52% from $180B the previous quarter. Its ten largest holdings account for 37% of the portfolio.
Baillie Gifford & Co's Q1 2021 filing shows 39 new, 260 increased, 115 reduced and 23 closed positions. Its largest new stake was Coupang: 22,054,023 shares worth $1.09B. The largest sale was Tesla, an estimated $8.35B.
By sector, the portfolio is most concentrated in Consumer Discretionary at 32% of assets, down from 38% a quarter earlier, followed by Healthcare and Technology.
- Baillie Gifford & Co's largest Q1 2021 buy was Coupang: 22,054,023 shares worth $1.09B.
- Baillie Gifford & Co added most to Moderna in Q1 2021, an estimated $3.05B increase.
- Baillie Gifford & Co's biggest Q1 2021 reduction was Tesla, cutting an estimated $8.35B.
- Baillie Gifford & Co fully exited Stellantis in Q1 2021, selling an estimated $533M.
- Baillie Gifford & Co's ten largest holdings make up 37% of its $179B portfolio in Q1 2021.
- Baillie Gifford & Co opened 39 new positions and closed 23 in Q1 2021.
- Baillie Gifford & Co's portfolio value fell 0.52% quarter-over-quarter to $179B.
Based on Baillie Gifford & Co's 13F filing for Q1 2021, filed 6 May 2021.